{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:23:55Z","timestamp":1760142235771,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.gastrohep.2024.502287","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T21:04:20Z","timestamp":1731618260000},"page":"502287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world clinical characteristics and therapeutic strategies in patients with moderate-to-severe inflammatory bowel disease in Argentina: Data from the RISE-AR study"],"prefix":"10.1016","volume":"48","author":[{"given":"Pablo Andres","family":"Olivera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domingo","family":"Balderramo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Sebastian","family":"Lasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Zubiaurre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"Correa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Lubrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orlando","family":"Ruffinengo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Yantorno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Rausch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisela","family":"Pi\u00f1ero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Bolomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Amigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jazmin","family":"El-Hakeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiana Beatriz","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Brion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Sambuelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2024.502287_bib0155","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S2468-1253(19)30358-9","article-title":"Global burden of inflammatory bowel disease","volume":"5","author":"Jairath","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2024.502287_bib0160","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2024.502287_bib0165","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2024.502287_bib0170","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.cgh.2019.06.030","article-title":"Progression of inflammatory bowel diseases throughout Latin America and the Caribbean: a systematic review","volume":"18","author":"Kotze","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2024.502287_bib0175","doi-asserted-by":"crossref","first-page":"4060648","DOI":"10.1155\/2020\/4060648","article-title":"Treatment adherence in inflammatory bowel disease patients from Argentina: a multicenter study","volume":"2020","author":"Lasa","year":"2020","journal-title":"Gastroenterol Res Pract"},{"key":"10.1016\/j.gastrohep.2024.502287_bib0180","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.dld.2021.01.006","article-title":"High ulcerative colitis and Crohn's disease ratio in a population-based registry from Cordoba, Argentina","volume":"53","author":"Balderramo","year":"2021","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.gastrohep.2024.502287_bib0185","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn's-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2024.502287_bib0190","doi-asserted-by":"crossref","first-page":"5862","DOI":"10.3748\/wjg.v25.i38.5862","article-title":"Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil","volume":"25","author":"Parra","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"Suppl. 8","key":"10.1016\/j.gastrohep.2024.502287_bib0195","article-title":"High disease burden of crohn's disease (CD) in a Latin American IBD reference center P0291 UEG virtual 2021","volume":"9","author":"Sambuelli","year":"2021","journal-title":"UEG J"},{"key":"10.1016\/j.gastrohep.2024.502287_bib0200","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.gastrohep.2023.09.012","article-title":"Incidence and prevalence of inflammatory bowel diseases in a population from Buenos Aires, Argentina","volume":"47","author":"Olivera","year":"2023","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2024.502287_bib0205","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.3748\/wjg.v22.i22.5267","article-title":"Inflammatory bowel disease: a descriptive study of 716 local Chilean patients","volume":"22","author":"Simian","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2024.502287_bib0210","doi-asserted-by":"crossref","first-page":"e24729","DOI":"10.1097\/MD.0000000000024729","article-title":"Trends in the epidemiology of inflammatory bowel disease in Colombia by demographics and region using a nationally representative claims database and characterization of inflammatory bowel disease phenotype in a case series of Colombian patients","volume":"100","author":"Juliao-Banos","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.gastrohep.2024.502287_bib0215","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3748\/wjg.v27.i2.208","article-title":"Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowel disease in Brazil","volume":"27","author":"Zaltman","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2024.502287_bib0220","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(09)61658-9","article-title":"M1155 prevalence of inflammatory bowel disease in a university hospital health maintenance organization","volume":"136","author":"Sobrero","year":"2009","journal-title":"Gastroenterology"},{"issue":"Suppl. 1","key":"10.1016\/j.gastrohep.2024.502287_bib0225","doi-asserted-by":"crossref","first-page":"S397","DOI":"10.1016\/S0016-5085(16)31390-7","article-title":"Sa1901 rates of colectomy in ulcerative colitis (UC) through time in a Latin-American unit of IBD","volume":"150","author":"Sambuelli","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2024.502287_bib0230","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1590\/s0004-2803.201900000-59","article-title":"Biological therapy penetration for inflammatory bowel disease in Latin America: current status and future challenges","volume":"56","author":"Quaresma","year":"2019","journal-title":"Arq Gastroenterol"},{"key":"10.1016\/j.gastrohep.2024.502287_bib0235","doi-asserted-by":"crossref","first-page":"e28624","DOI":"10.1097\/MD.0000000000028624","article-title":"Clinical differentiation of inflammatory bowel disease (IBD) in Latin America and the Caribbean","volume":"101","author":"Yamamoto-Furusho","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.gastrohep.2024.502287_bib0240","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohn's disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2024.502287_bib0245","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/ibd\/izy083","article-title":"Genetic markers predict primary nonresponse and durable response to anti-tumor necrosis factor therapy in ulcerative colitis","volume":"24","author":"Burke","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2024.502287_bib0250","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.crohns.2010.04.004","article-title":"Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects","volume":"4","author":"Allez","year":"2010","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2024.502287_bib0255","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.gastrohep.2023.04.002","article-title":"Suboptimal response to tumor necrosis factor antagonists in inflammatory bowel disease in Latin America: EXPLORE LATAM study","volume":"47","author":"Balderramo","year":"2024","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2024.502287_bib0260","doi-asserted-by":"crossref","first-page":"867","DOI":"10.5009\/gnl20353","article-title":"Real-world incidence of suboptimal response to anti-tumor necrosis factor therapy for ulcerative colitis: a nationwide population-based study","volume":"15","author":"Shin","year":"2021","journal-title":"Gut Liver"},{"key":"10.1016\/j.gastrohep.2024.502287_bib0265","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.dld.2017.07.010","article-title":"Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease","volume":"49","author":"Lindsay","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.gastrohep.2024.502287_bib0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175099","article-title":"Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States","volume":"12","author":"Patel","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.gastrohep.2024.502287_bib0275","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211006669","article-title":"Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches","volume":"14","author":"Privitera","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.gastrohep.2024.502287_bib0280","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2024.502287_bib0285","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2024.502287_bib0290","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S2468-1253(21)00312-5","article-title":"Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis","volume":"6","author":"Singh","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2024.502287_bib0295","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/ecco-jcc\/jjab058","article-title":"Vedolizumab and anti-TNFalpha real-world outcomes in biologic-naive inflammatory bowel disease patients: results from the EVOLVE study","volume":"15","author":"Bressler","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2024.502287_bib0300","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231159452","article-title":"Is there an optimal sequence of biologic therapies for inflammatory bowel disease?","volume":"16","author":"Bressler","year":"2023","journal-title":"Therap Adv Gastroenterol"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570524002991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570524002991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:49:39Z","timestamp":1760082579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570524002991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0210570524002991"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2024.502287","relation":{},"ISSN":["0210-5705"],"issn-type":[{"type":"print","value":"0210-5705"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world clinical characteristics and therapeutic strategies in patients with moderate-to-severe inflammatory bowel disease in Argentina: Data from the RISE-AR study","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2024.502287","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"502287"}}